French Multicenter 22-Year Experience in Stem Cell Transplantation for Beta-Thalassemia Major: Lessons and Future Directions

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 62-68

  Galambrun, Claire ^a,b   Pondarré, Corinne ^b,c   Bertrand, Yves ^b,c   Loundou, Anderson ^d   Bordigoni, Pierre ^e   Frange, Pierre ^f   Lutz, Patrick ^g   Mialou, Valérie ^b,c   Rubie, Hervé ^h   Socié, Gérard ⁱ   Schneider, Pascale ^j   Bernaudin, Françoise ^k   Paillard, Catherine ^l   Michel, Gérard ^a,b   Badens, Catherine ^a,b   Thuret, Isabelle ^a,b  

^a TIMONE HOSPITAL   (France)

^b Rare Disease Center for Thalassemia   (France)

^c Institut d'Hematologie et d'Oncologie Pediatrique   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e CHU NANCY BRABOIS   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h HÔPITAL DES ENFANTS   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j HÔPITAL CHARLES NICOLLE   (France)

^k CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^l HÔTEL DIEU   (France)

more..

Author keywords

Antithymocyte globulin; HSC transplant; Thalassemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; SIBLING; SURVIVAL RATE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BUSULFAN; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871922030     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.005     Document Type: Article

References (36)

1. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
2. Cavazzana-Calvo M., Payen E., Negre O., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassemia. Nature 2010, 467:318-322.
3. Lucarelli G., Galimberti M., Polchi P., et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990, 322:417-421.
4. Giardini C., Angelucci E., Lucarelli G., et al. Bone marrow transplantation for thalassemia: experience in Pesaro, Italy. Am J Pediatr Hematol Oncol 1994, 16:6-10.
5. Angelucci E., Baronciani D. Allogeneic stem cell transplantation for thalassemia major. Haematologica 2008, 93:1780-1781.
6. Ball L.M., Lankester A.C., Giordano P.C., et al. Paediatric allogeneic bone marrow transplantation for homozygous beta-thalassaemia, the Dutch experience. Bone Marrow Transplant 2003, 31:1081-1087.
7. Lawson S.E., Roberts I.A.G., Amrolia P., et al. Bone marrow transplantation for beta-thalassaemia major: the UK experience in two paediatric centres. Br J Haematol 2003, 120:289-295.
8. Hongeng S., Pakakasama S., Chuansumrit A., et al. Outcomes of transplantation with related and unrelated donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant 2006, 12:683-687.
9. Ramzi M., Nourani H., Zakerinia M., et al. Results of hematopoietic stem cell transplant in Shiraz: 15 years' experience in southern Iran. Exp Clin Transplant 2010, 8:61-65.
10. Fang J.P., Xu L.H. Hematopoietic stem cell transplantation for children with thalassemia major in China. Pediatr Blood Cancer 2010, 55:1062-1065.
11. Sabloff M., Chandy M., Wang Z., et al. HLA-matched sibling bone marrow transplantation for thalassemia major. Blood 2011, 117:1745-1750.
12. Goussetis E., Peristeri I., Kitra V., et al. HLA-matched sibling stem cell transplantation in children with beta-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience. Bone Marrow Transplant 2012, 47:1061-1066.
13. Thuret I., Pondarre C., Loundou A., et al. Complications of patients with β-thalassemia in France: results of the National Registry. Haematologica 2010, 95:724-729.
14. La Nasa G., Argiolu F., Giardini C., et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of Italian Bone Marrow Transplant Group. Ann NY Acad Sci 2005, 1054:186-195.
15. Lucarelli G., Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008, 22:53-63.
16. Lisini D., Zecca M., Giorgiani G., et al. Donor/recipient mixed chimerism does not predict graft failure with β-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica 2008, 93:1859-1867.
17. Lucarelli G., Clift R.A., Galimberti M., et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996, 87:2082-2088.
18. Sodani P., Gaziev D., Polchi P., et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004, 104:1201-1203.
19. Gaziev J., Sodani P., Lucarelli G., et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant 2008, 42:397-404.
20. Lucarelli G., Clift R.A., Galimberti M., et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999, 93:1164-1167.
21. Bernaudin F., Socié G., Kuentz M., SFGM-TC, et al. Long-term results of related myeloablative stem cell transplantation to cure sickle cell disease. Blood 2007, 110:2749-2756.
22. Cazzola M., De Stefano P., Ponchio L., et al. Relationship between transfusion regimen and suppression of erythropoiesis in β-thalassemia major. Br J Haematol 1995, 89:473-478.
23. Cazzola M., Borgna-Pignatti C., Locatelli F., et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997, 37:135-140.
24. Olivieri N.F. The beta-thalassemias. N Engl J Med 1999, 341:99-109.
25. Pondarre C., Thuret I., Galambrun C., et al. Recommandations pour les greffes de cellules souches hématopoïétiques dans les bêta-thalassémies. Correspond Onco-Hématol 2012, 7:45-50.
26. Mathews V., George B., Lakshmi K.M., et al. Impact of pretransplant splenectomy on patients with β-thalassemia major undergoing a matched-related allogeneic stem cell transplantation. Pediatr Transplant 2009, 103:171-176.
27. Isgro A., Gaziev J., Sodani P., et al. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Ann NY Acad Sci 2010, 1202:149-154.
28. Steffens H.P., Podlech J., Kurz S., et al. Cytomegalovirus inhibits the engraftment of donor bone marrow cells by downregulation of hematopoietic gene expression in recipient stroma. J Virol 1998, 72:5006-5015.
29. Gaziev D., Polchi P., Galimberti M., et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997, 63:854-860.
30. Locatelli F., Rocha V., Reed W., et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003, 101:2137-2143.
31. Pinto F.O., Roberts I. Cord blood stem cell transplantation for haemoglobinopathies. Br J Haematol 2008, 141:309-324.
32. Boncimino A., Berating A., Locatelli F. Cord blood transplantation in patients with hemoglobinopathies. Transfus Apheresis Sci 2010, 42:277-281.
33. Vassal G., Michel G., Esperou H., et al. Prospective validation of novel IV busulfan fixed dosing for pediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008, 61:113-123.
34. Gaziev J., Nguyen L., Puozzo C., et al. Novel pharmacokinetic behaviour of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010, 115:4597-4604.
35. Bernardo M.E., Zecca M., Piras E., et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol 2008, 143:548-551.
36. Cappelli B., Chiesa R., Evangelio C., et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol 2009, 147:554-560.